Cyclic adenosine-3',5'-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma

Clinical Cancer Research

Volumn 3, Issue 10, 1997, Pages 1781-1787

  Krett, Nancy L ^a,b   Zell, JoAnn L ^a   Halgren, Robert G ^a   Pillay, Shafali ^a   Traynor, Ann E ^a   Rosen, Steven T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CHROMATIN CONDENSATION; CYTOLYSIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MYELOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; BUCLADESINE; BUTYRATES; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FORSKOLIN; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0030796704     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Alexanian, R., and Dimopoulos, M. The treatment of multiple myeloma. N. Engl. J. Med., 330: 484-489, 1994.
2. rd Annual Meeting, pp. 135-141. Philadelphia: W. B. Saunders Co., 1997.
3. Cho-Chung, Y. S. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res., 50: 7093-7100, 1990.
4. Daniel, V., Litwack, G., and Tomkins, G. M. Induction of cytolysis of cultured lymphoma cells by adenosine 3′, 5′-cyclic monophosphate and the isolation of resistant variants. Proc. Natl. Acad. Sci. USA, 70: 76-79, 1973.
5. Vedeckis, W. V., and Bradshaw, H. D. DNA fragmentation in S49 lymphoma cells killed with glucocorticoids and other agents. Mol. Cell. Endocrinol., 30: 215-227, 1983.
6. Gruol, D. J., and Dalton, D. K. Phenothiazines cause a shift in the cAMP dose-response: selection of resistant variants in a murine thymoma line. J. Cell. Physiol., 119: 107-118, 1984.
7. Tigyi, G., Dyer, D. L., and Miledi, R. Lysophosphatidic acid possesses dual action in cell proliferation. Proc. Natl. Acad. Sci. USA, 91: 1908-1912, 1994.
8. Rezzonico, R., Loubat, A., Lallemand, D., Pfarr, C. M., Far, D. F., Proudfoot, A., Rossi, B., and Ponzio, G. Cyclic AMP stimulates a JunD/Fra-2 AP-1 complex and inhibits the proliferation of interleukin-6-dependent cell lines. Oncogene, 11: 1069-1078, 1995.
9. Lee, M-R., Liou, M-L., Liou, M-L., Yang, Y-F., and Lai, M-Z. cAMP analogs prevent activation-induced apoptosis of T-cell hybridomas. J. Immunol., 151: 5208-5217, 1993.
10. Spaulding, S. W. The ways in which hormones change cyclic adenosine 3′, 5′-monophosphate-dependent protein kinase subunits, and how such changes affect cell behavior. Endocr. Rev., 14: 632-650, 1993.
11. Dowd, D. R., and Miesfeld, R. L. Evidence that glucocorticoid-and cyclic AMP-induced apoptotic pathways in lymphocytes share distal events. Mol. Cell. Biol., 12: 3600-3608, 1992.
12. Dowd, D. R., MacDonald, P. N., Domm, B. S., Haussier, M. R., and Miesfeld, R. L. Stable expression of the calbindin-D28K complementary DNA interferes with the apoptotic pathway in lymphocytes. Mol. Endocrinol., 6: 1843-1848, 1992.
13. Goldman-Leikin, R. E., Salwen, H. R., Herst, C. V., Variakojis, D., Bian, M., Lebeau, M., Selvanayagan, P., Marder, R., Andersen, R., Weitzman, S., and Rosen, S. T. Characterization of a novel myeloma line. J. Lab. Clin. Medicine, 113: 335-345, 1989.
14. Moalli, P. A., Pillay, S., Weiner, D., Leikin, R., and Rosen, S. T. A mechanism of resistance to glucocorticoid in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood, 79: 213-222, 1992.
15. Sambrook, J., Fritsch, E. F., and Maniatis, T. (eds). Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
16. Gong, J., Traganos, F., and Darzynkiewicz, Z. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal. Biochem., 218: 314-319, 1994.
17. 1-S transition in mammary carcinoma cells (MCF-7). Endocrinology, 136: 2513-2520, 1995.
18. Gomi, M., Moriwaki, K., Katagiri, S., Kurata, Y., and Thompson, E. B. Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA. Cancer Res., 50: 1873-1878, 1990.
19. Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H., and Epstein, J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood, 84: 3063-3070, 1994.
20. Barut, B. A., Zon, L. I., Cochran, M. K., Paul, S. R., Chauhan, M., Mohrbacher, A., Fingeroth, J., and Anderson, K. C. Role of interleukin 6 in the growth of myeloma-derived cell lines. Leuk. Res., 16: 951-959, 1992.
21. Kieffer, J., Okret, S., Jondal, M., and McConkey, D. J. Functional glucocorticoid receptor expression is required for cAMP-mediated apoptosis in a human leukemic T cell line. J. Immunol., 155: 4525-4528, 1995.
22. Rangarajan, P. N., Umesono, K., and Evans, R. M. Modulation of glucocorticoid receptor function by protein kinase A. Mol. Endocrinol., 6: 1451-1457, 1992.
23. Moyer, M. L., Borro, K. C., Bona, B. J., DeFranco, D. B., and Nordeen, S. K. Modulation of cell signaling pathways can enhance or impair glucocorticoid-induced gene expression without altering the state of receptor phosphorylation. J. Biol. Chem., 268: 22933-22940, 1993.
24. Gruol, D. J., and Altschmied, J. Synergistic induction of apoptosis with glucocorticoids and 3′, 5′-cyclic adenosine monophosphate reveals agonist activity by RU 486. Mol. Endocrinol., 7: 104-113, 1993.
25. Gruol, D. J., Campbell, F. N., and Bourgeois, S. Cyclic AMP-dependent protein kinase promotes glucocorticoid receptor function. J. Biol. Chem., 261: 4909-4914, 1986.
26. Bursch, W., Kleine, L., and Tenniswood, M. The biochemistry of cell death by apoptosis. Biochem. Cell Biol., 68: 1071-1074, 1990.
27. Tortora, G., Ciadiella, F., Pepe, S., Taliaferri, P., Ruggiero, A., Bianco, C., Guarrasi, R., Miki, K., and Bianco, A. R. Phase I clinical study with 8-chloro-cAMP and evaluation of immunological effects in cancer patients. Clin. Cancer Res., 1: 377-384, 1995.